Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. News
  7. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Epizyme : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to $5 From $10

08/10/2021 | 08:11am EDT


© MT Newswires 2021
All news about EPIZYME, INC.
10/08EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
10/07EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/15EPIZYME : Announces Data from TAZVERIK (Tazemetostat) Clinical Programs to be Presented Du..
AQ
09/14EPIZYME : Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented D..
BU
08/23EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
08/20EPIZYME : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
08/16EPIZYME : FIFTH AMENDMENT TO LEASE (Form 8-K)
PU
08/16EPIZYME, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhib..
AQ
08/10EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to ..
MT
08/10EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintains Buy Rati..
MT
More news
Analyst Recommendations on EPIZYME, INC.
More recommendations
Financials (USD)
Sales 2021 53,4 M - -
Net income 2021 -225 M - -
Net cash 2021 96,4 M - -
P/E ratio 2021 -2,26x
Yield 2021 -
Capitalization 506 M 506 M -
EV / Sales 2021 7,68x
EV / Sales 2022 4,02x
Nbr of Employees 304
Free-Float 80,9%
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 4,95 $
Average target price 11,14 $
Spread / Average Target 125%
EPS Revisions
Managers and Directors
Grant C. Bogle President, Chief Executive Officer & Director
Matthew E. Ros Chief Financial Officer
David M. Mott Chairman
Shefali Agarwal Executive VP, Chief Medical & Development Officer
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-54.42%506
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156